These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3102725)

  • 61. Verification of the biological properties of Au-195 labeled gold sodium thiomalate by activation analysis.
    Smith EM; Smith PM; Gottlieb NL
    J Nucl Biol Med; 1975; 19(1):32-5. PubMed ID: 806668
    [No Abstract]   [Full Text] [Related]  

  • 62. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis.
    Palit J; Hill J; Capell HA; Carey J; Daunt SO; Cawley MI; Bird HA; Nuki G
    Br J Rheumatol; 1990 Aug; 29(4):280-3. PubMed ID: 2116206
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The in vivo effect of triethylphosphine gold (auranofin), sodium aurothiomalate and azathioprine on natural killer cell activity of patients with rheumatoid arthritis.
    Abom B; Pedersen BK
    Clin Exp Rheumatol; 1987; 5(1):47-52. PubMed ID: 3109798
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Correlation of in vitro and in vivo effects of gold compounds on leukocyte function: possible mechanisms of action.
    Wolach B; DeBoard JE; Coates TD; Baehner RL; Boxer LA
    J Lab Clin Med; 1982 Jul; 100(1):37-44. PubMed ID: 6283001
    [TBL] [Abstract][Full Text] [Related]  

  • 65. beta 2 microglobulin plasma levels reflect disease activity in rheumatoid arthritis.
    Crisp AJ; Coughlan RJ; Mackintosh D; Clark B; Panayi GS
    J Rheumatol; 1983 Dec; 10(6):954-6. PubMed ID: 6420563
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes.
    Scheinberg MA; Santos LM; Finkelstein AE
    J Rheumatol; 1982; 9(3):366-9. PubMed ID: 6288942
    [TBL] [Abstract][Full Text] [Related]  

  • 67. II. Unbound versus total serum gold concentration: pharmacological actions on cellular function.
    Lorber A; Kunishima DH; Harralson AF; Simon TM
    J Rheumatol; 1983 Aug; 10(4):568-73. PubMed ID: 6413684
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of neovascularization in vivo by gold compounds.
    Saura R; Matsubara T; Mizuno K
    Rheumatol Int; 1994; 14(1):1-7. PubMed ID: 7939134
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [TBL] [Abstract][Full Text] [Related]  

  • 70. All that glitters may be HMGB1: an interview with Dr. Ulf Andersson.
    Ulf A
    J Leukoc Biol; 2008 Jan; 83(1):39-40. PubMed ID: 17965336
    [No Abstract]   [Full Text] [Related]  

  • 71. [Distribution of gold from aurothiomalate and gold trielthylphosphine in whole blood, lymphocytes and lymphocyte chromatin of patients with chronic polyarthritis].
    Teherani DK; Altmann H; Tausch G; Eberl R
    Wien Klin Wochenschr Suppl; 1984; 156():53-5. PubMed ID: 6442060
    [No Abstract]   [Full Text] [Related]  

  • 72. Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis.
    Sambrook PN; Browne CD; Champion GD; Day RO; Vallance JB; Warwick N
    J Rheumatol; 1982; 9(6):932-4. PubMed ID: 6819360
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second-line drug therapy.
    Crilly A; Madhok R; Watson J; Capell HA; Sturrock RD
    Br J Rheumatol; 1994 Sep; 33(9):821-5. PubMed ID: 7915945
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Gold therapy of rheumatic diseases].
    Berndt H
    Z Arztl Fortbild (Jena); 1987; 81(9):416. PubMed ID: 3114970
    [No Abstract]   [Full Text] [Related]  

  • 75. [Studies on cellular protein synthesis in synovial fluid following intraarticular gold administration (author's transl)].
    Bröll H; Altmann H; Kocsis F; Eberl R
    Arzneimittelforschung; 1978; 28(12):2352-4. PubMed ID: 115476
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Partial cross-resistance between auranofin and sodium aurothiomalate in cultured human cells.
    Rugstad HE; Glennås A
    Scand J Rheumatol; 1988; 17(3):175-81. PubMed ID: 3140371
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early and late changes in sulphydryl group and copper protein concentrations and activities during drug treatment with aurothiomalate and auranofin.
    Rae KJ; Mackay CN; McNeil CJ; Brown DH; Smith WE; Lewis D; Capell HA
    Ann Rheum Dis; 1986 Oct; 45(10):839-46. PubMed ID: 3098194
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of auranofin and myochrysine on intestinal transport and morphology in the rat.
    Ammon HV; Fowle SA; Cunningham JA; Komorowski RA; Loeffler RF
    Gut; 1987 Jul; 28(7):829-34. PubMed ID: 3115869
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The action of myocrisin on membrane bound sulphhydryl groups.
    McCrae F; Reglinski J; Smith WE; Brzeski M; Sturrock RD
    Clin Chim Acta; 1990 Dec; 195(1-2):41-5. PubMed ID: 1982710
    [No Abstract]   [Full Text] [Related]  

  • 80. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin.
    Darabi F; Marzo T; Massai L; Scaletti F; Michelucci E; Messori L
    J Inorg Biochem; 2015 Aug; 149():102-7. PubMed ID: 25865000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.